
Shares of EBR Systems EBR.AX advance as much as 5.52% to A$0.955, their highest point since December 4
The medtech co reportsfirst patient enrolment and implant in a totally leadless cardiac resynchronization therapy (CRT) study, which could "meaningfully expand" its addressable market
Adds that the study marks a key milestone as it tests WiSE for a potential first-line heart failure therapy
Stock down 9.3% YTD, including the day's moves